MedTrace Logo

The Effect of Transcranial Direct Current Stimulation on Visual Attention in Mild Cognitive Impairment

NCT03974087 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2023-03-15

No results posted yet for this study

Summary

Progressively causes the breakdown of cognitive functions and impairs quality of life for patients and their caregivers. In addition to memory impairment, visual attention is also compromised, even at the stage of mild cognitive impairment due to AD (MCI-AD). No treatment has been found for MCI-AD; therefore, attention has been drawn to non-invasive brain stimulation techniques, such as transcranial direct current stimulation (tDCS), in order to enhance cognitive functions by modifying brain plasticity. In the current research, investigator aim to examine the long-term effects of the optimal multiple-session tDCS protocol in MCI-AD on visual attention including the transfer to an ecologically valid virtual environment and identify the neural underpinnings of tDCS-induced behavioral aftereffects using a combined tDCS/ MRI network-based approach.

Conditions

Interventions

DEVICE

Transcranial Direct Current Stimulation (tDCS)

2mA stimulation for 20 minutes

Sponsors & Collaborators

  • St. Anne's University Hospital Brno, Czech Republic

    collaborator OTHER

  • Masaryk University

    lead OTHER

Principal Investigators

  • Lubomira Anderková, PhD · Ceitec, Masaryk University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-19
Primary Completion
2022-10-30
Completion
2022-12-30

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03974087 on ClinicalTrials.gov